Alla fine hai tirato fuori la perla...
si porta al mercato superiore....MAYBE:D:D:D:D

studia per massacrare il cancro + indegno
Adamis Reports APC-300 Kills Human Pancreatic Cancer Cells

se trova la soluzione ADDIO$$$$$$$$$$$$$$$$$$

its drug APC-300 significantly inhibits the growth of pancreatic cancer cells. Pancreatic cancer still remains one of the most deadly forms of all cancers. The mortality from pancreatic cancer compares strikingly with its incidence. It has one of the worst prognoses with an overall survival rate of less than 5% and with most of the patients dying within the first two years. Recent results regarding the mechanism leading to the occurrence of pancreatic cancer suggest that in more than 90% of pancreatic cancers the Ras oncogene has been mutated. The mutation of the Ras oncoprotein has been linked to the induction of multiple signaling pathways within the cell which leads to the resistance of those cells to apoptosis (cell death) and the emergence of cancer.

In an attempt to understand how APC-300 works, Dr. Hasan Mukhtar and his team at the University of Wisconsin, have taken human pancreatic adenocarcinoma cells and investigated the effect of APC-300 on tumor cell growth and on the modulation of multiple Ras induced signaling pathways. APC-300 treatment of cancer cells was found to significantly reduce the expression of Ras oncoprotein and to modulate the protein expression of various signaling molecules involved in cancer cell growth. APC-300 attacks the cancer cells at multiple signaling pathways leading to tumor cell death and the inhibition of the growth of pancreatic cancer cells (Life Sciences, 2011 (88) pp. 285-293 and Cancer Res. 2009, 69(3) 1156-65.).

Additionally, in a mouse pancreatic cancer model, APC-300 was shown to significantly reduce the growth of tumors (p<0.01). Collectively, the data show that APC-300 induces apoptosis leading to the reduced tumorgenicity of human pancreatic cancer cells in the mouse tumor model and the killing of cancer cells in vitro. It is believed that one of the advantages of APC-300 is that it has the ability to intervene at more than one critical pathway in the pancreatic cancer cell process.

Dr. Dennis J. Carlo, Ph.D., President and CEO of Adamis states that, “Because of the known mechanisms of action of APC-300, and its ability to effect multiple signaling targets within the cancer cell, this drug will likely be active against different tumors. In fact, the data we have to date, support that to be the case.”
speriamo in bene ELISA....:D:D:D:D
a prestoooooooooooooooooooooo!
Adamis Reports APC-300 Kills Human Prostate Cancer Cells

that in addition to activity in pancreatic cancer and its multiple modes of action, APC-300 significantly inhibits the growth of prostate cancer cells.

In 2010, the American Cancer Society reported that 217,730 men in the U.S. were diagnosed with prostate cancer and 32,050 were projected to die from the disease. While treatment with surgery and/or radiation is often successful, about one-third of patients will experience disease recurrence. Despite the initial success of androgen deprivation therapy (castration), prostate cancer continues to progress from androgen-dependent prostate cancer (ADPC) to castrate-resistant prostate cancer (CRPC) in most of these patients within a matter of years. More and more data point to the fact that androgen receptor (AR) plays a central role in both ADPC and CRPC. Therefore, identifying inhibitors of AR signaling which can act independent of hormonal status is of prime importance. These types of inhibitors could prove to be very important in the treatment of prostate cancer and thereby prevent or delay ADPC from progressing to CRPC. Based on the most recent information, APC-300 could very well be a molecule that acts independent of hormonal status.

A study published in Clinical Cancer Research (June 28, 2011) and authored by Dr. Mohammad Saleem and his associates from the Hormel Institute, University of Minnesota and the Mayo Clinic showed that APC-300 inhibits AR signaling and activation in prostate cancer in both ADPC and CRPC. Agents that have the potential to combat prostate cancer under both conditions (androgen and non-androgen responsive environments) are rare, but obviously desirable. APC-300 has been shown to have this desired activity. The results of the current study are significant because they demonstrate that APC-300, while sparing normal cells, preferentially inhibits the growth and proliferation of heterogeneous prostate cancer cells representing differential androgen sensitivity and AR expression status. Also, the observation that APC-300 sensitized highly aggressive CRPC cells to bicalutamide (currently used to treat ADPC) has high clinical relevance.

Additionally, APC-300 was shown to decrease messenger RNA and protein expression of the AR-target gene, PSA (biomarker for prostate cancer) in ADPC and CRPC cells. This translated into APC-300 showing a decrease in the secreted levels of PSA in a concentration dependent manner and a decrease in the growth of prostate cancer cells in vitro and in vivo. The data provide good evidence that APC-300 has the potential to decrease the AR transcriptional activity of ADPC and CRPC cells by blocking the AR occupancy on AR-responsive elements in target genes. The data also show that APC-300 had a significant effect on reducing the growth of ADPC and CRPC and reducing the levels of PSA in the mouse tumor model. Taken together, these data suggest that APC-300 may very well play a significant role in the treatment of prostate cancer.

Dennis J. Carlo, Ph.D., President and CEO of Adamis, states that, “We continue to build upon our prostate cancer franchise. New independent published data validate the importance of our three compounds (APC-100, 200, 300) for the treatment of prostate and pancreatic cancer. We will continue to focus and aggressively move these compounds into the clinic. Molecules such as APC-300 could very well work alone, but also just as important, APC-300 may enhance the activity of compounds already marketed and used for the treatment of prostate cancer.”
questa è ancora un azienda vergine
poca gente è al corrente di quello che sta facendo!

non c'è cura al monento
per il cancro al pancreas
admp..ha messo le fondamenta x curare questa bestia
dite che non è a rischio di eventuali patatrac a sorpresa???

Adamis Prostate Cancer Drug APC-100 Granted a Patent in US

announced the technology which constitutes its compound APC-100 was recently granted a patent in the United States. A patent entitled “Chroman-Derived Compounds for the Treatment of Cancer” has been issued. This patent, together with earlier issued European and US patents, significantly strengthens the Adamis APC-100 patent portfolio for the use of APC-100 in the treatment of early and late stage prostate cancer. Claims include a method of: i.) inhibiting the growth of prostate cancer cells; ii.) delaying the progression of prostate cancer; and, iii.) preventing the recurrence of prostate cancer.

Adamis recently announced that it had received approval from the FDA to begin Phase 1/2a clinical studies with APC-100 in men with castrate resistant prostate cancer (CRPR). Each patient will be assessed for toxicity, biochemical responses (Prostate Specific Antigen), radiographic and clinical responses. The study is scheduled to begin shorty. It will start at the University of Wisconsin Carbone Cancer Center and then be extended to Wayne State University Karmanos Cancer Institute. Both of these Institutions are currently named within “The Prostate Cancer Clinical Trials Consortium”. This Clinical Trials Consortium or Prostate Cancer Centers of Excellence is made up of a 13 member clinical trial research group that capitalizes on their scientific expertise and unique institutional resources in order to rapidly bring new discoveries to prostate cancer patients.

APC-100 has multiple modes of action. It is an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor drug. APC-100 has demonstrated to have higher therapeutic activity than the current marketed Standard of Care anti-androgens. Pre-clinical studies confirming the use of APC-100 for the treatment of prostate cancer were pioneered by Dr. George Wilding and his team. Dr. Wilding is the Assistant Dean for Oncology and Director of the University of Wisconsin Carbone Cancer Center. In addition to increasing time to tumor progression and survival, APC-100 also induced a significant decrease in PSA production. These characteristics make APC-100 a first-in-class compound for the potential treatment of both castrate-sensitive and castrate-resistant prostate cancer.

APC-100 has previously received the National Cancer Institute's (NCI) multi-year, multi-million dollar RAPID Award (Rapid Access to Preventative Intervention Development). Each year, this award is given by the NCI Division of Cancer Prevention, under the RAPID Program, to what it believes are the most promising new preventative/therapeutic anti-cancer drugs.

Previously, development of APC-100 has been funded by Michael Milken's Prostate Cancer Foundation (PCF, formerly CapCure), the Department of Defense’s Congressionally Directed Medical Research Programs’ (CDMRP) Prostate Cancer Research Program (PCRP), as well as grants and contracts from the NCI.

Dr. Dennis J. Carlo, President and CEO of Adamis stated, “We have assembled a substantial prostate cancer franchise and we will continue to aggressively strengthen our patent portfolio. Protecting our technology is of upmost importance and critical to our success. We continue to make advances on this front and just recently received European coverage that broadly protects our cancer vaccine program.”
SOLDI CHE ENTRANO$$$$$$$$$$$$$$$$$$

Adamis Receives Another Milestone Payment

previously entered into a common stock purchase agreement in November 2010 to allow an investor to purchase $10 million of common stock at $.25 per share. The investor purchased $5 million in November 2010 and the agreement provided for two subsequent closings of $2.5 million each if certain milestones have been achieved. The two sets of milestones primarily relate to our telomerase prostate cancer technology and to the Company’s APC-100 prostate cancer product candidate.

The first set of milestones has been achieved and under the agreement as amended, the company received $550,000 of the milestone payment in June and now has received $550,000 in July. The agreement provides that the $1,400,000 balance of the first milestone payment will be made on or before September 29, 2011. Under the agreement, the outside date for achievement of the second set of milestones is December 31, 2011. The Company currently believes that it will achieve the milestone conditions relating to the second $2.5 million milestone closing in advance of that date.

Dr. Dennis J. Carlo, President and CEO of Adamis stated, “The milestone payments will permit the Company to continue to move both our specialty pharmaceutical drugs and our clinical prostate cancer programs forward. On the specialty pharmaceutical side, the developmental work should be completed for two of the three products before the end of the calendar year. The developmental work includes the completion of the components and formulation required to advance the products to our manufacturing partner, Beximco. These products are indicated for asthma, chronic obstructive pulmonary disease, and allergic rhinitis. On the therapeutics side of the business, the additional funds permit us to move APC-100 into a Phase 1/2a clinical study and our prostate vaccine into a Phase 2 study.”